INTRODUCTION {#s05}
============

Non--small-cell lung cancer (NSCLC) is a heterogeneous disease composed of unique molecular subsets with distinct clinical outcomes.^[@B1],[@B2]^ Multiple randomized studies have established the superiority of molecularly targeted therapies versus chemotherapy for the treatment of *EGFR*-mutant and *ALK*-positive NSCLC.^[@B3]-[@B6]^ In other molecular subsets, single-arm studies confirm that treatment with targeted therapies can induce durable responses.^[@B7],[@B8]^ As drugs that target these molecular drivers are approved for first-line treatment, genotyping in newly diagnosed NSCLC is considered the standard of care.^[@B9]^

Because of the need to interrogate a growing number of genes, next-generation sequencing (NGS) has largely replaced traditional single-gene assays.^[@B10]^ Guidelines endorsed by oncology and pathology societies recommend that molecular testing turnaround times not exceed 10 working days.^[@B9]^ Genotyping by NGS requires complex bioinformatics that can create treatment delays. Some patients with NSCLC present with symptomatic disease that requires initiation of treatment before molecular testing results are available.^[@B11]^ To our knowledge, the impact of molecular testing turnaround time on clinical decision making has not been formally assessed in NSCLC.

Here, we evaluated whether the addition of an epidermal growth factor receptor (EGFR)­--specific assay to NGS at diagnosis produced accurate results and reduced time to initiation (TTI) of EGFR-directed therapy. We selected *EGFR*-mutant NSCLC on the basis of its relatively high prevalence (10% to 15%) among patients with NSCLC,^[@B12]^ the lack of overlap between *EGFR* mutations and other clinically relevant molecular alterations,^[@B13]^ and the fact that EGFR inhibitors were readily available for hospitalized patients. We hypothesized that concurrent rapid genotyping would improve clinical care without compromising comprehensive NGS-based genotyping efforts.

MATERIALS AND METHODS {#s06}
=====================

Study Design {#s07}
------------

We conducted a multiphase, multidisciplinary quality improvement initiative from January 2015 to March 2018. In the first phase (January 2015 to May 2017), rapid *EGFR* testing was performed on tissue specimens from consecutive patients diagnosed with metastatic NSCLC who were never smokers/minimal smokers (≤ 10 pack years) or who were hospitalized at the time of diagnosis (Data Supplement). The second phase (May 2017 to September 2017) explored the impact of a multidisciplinary same-day fresh-tissue protocol (ultra-rapid testing). Specimens from both phases were submitted for NGS-based genotyping ([Fig 1](#f1){ref-type="fig"}). We also identified a comparator population composed of 121 patients with *EGFR*-mutant NSCLC who were diagnosed before implementation of the rapid testing (ie, historical cohort; Data Supplement). We extracted clinicopathologic features, molecular testing results, and treatment histories from the medical record. Follow-up data were obtained through November 2017. To assess operational sustainability, we analyzed testing patterns during a subsequent standard of care testing period (July 2017 to March 2018). The Massachusetts General Hospital institutional review board approved this study; all participants provided written informed consent.

![Rapid *EGFR* testing approach. We implemented rapid *EGFR* testing in parallel to genotyping using next-generation sequencing (NGS; compare pathway A *v* B). As a result of differences in reporting times, detection of an actionable *EGFR* mutation with rapid testing might lead to a treatment decision before NGS results are obtained. Note that there is a (variable) delay from reporting to treatment decision and initiation of therapy because of cost-coverage determination, preauthorization requirements, etc.The ultra-rapid *EGFR* testing pathway (pathway C) is a multidisciplinary workflow designed to improve turnaround time using fresh tissue (frozen sections) to extract nucleic acids. Note that ultra-rapid testing combines preanalytical improvements with the optimized rapid workflow and allows coupling with NGS (Data Supplement). Dx, diagnosis; FNA, fine-needle aspiration; Neg, negative; PCR, polymerase chain reaction; Pos, positive; QC, quality control; TKI, tyrosine kinase inhibitor.](PO.17.00299f1){#f1}

Molecular Analysis {#s08}
------------------

**Rapid assay.** Tumor DNA was extracted from formalin-fixed paraffin-embedded samples (rapid) or fresh-frozen sections (ultra-rapid) in a Clinical Laboratory Improvement Amendments--certified laboratory and was analyzed using a multiplexed polymerase chain reaction (PCR) assay.^[@B14]^ Multiplex PCR single-base extension sequencing technology (Snapshot; Applied Biosystems, Foster City, CA) was used to analyze the *EGFR* c.2573T (p.L858) and c.2369C (p.T790) residues. A separate PCR reaction with primers that flanked *EGFR* exon 19 was used to detect in-frame activating insertions or deletions in *EGFR*.^[@B14]^ The analytical sensitivity for this assay was approximately 5%.

**NGS.** Isolated nucleic acids from tumor specimens were analyzed with our NGS assay that uses anchored multiplex PCR to detect single-nucleotide variants and insertions/deletions in a target set of cancer-related genes.^[@B15]^ In addition, we examined fusion transcripts and *MET* exon 14 skipping by using an RNA-based NGS solid-fusion assay.^[@B15]^

Statistical and Economic Analysis {#s11}
---------------------------------

For contingency analyses, we used *t* tests, Fisher's exact tests, and χ^2^ statistics. We defined turnaround-time from the date of accessioning to the date of reporting, and we defined TTI from the date of the diagnostic biopsy to the date of ingestion of an EGFR tyrosine kinase inhibitor (TKI). We compared the TTI of EGFR-directed therapy in the rapid and historical groups by using event plots and log-rank statistics. For economic assessment, we reviewed line items of reimbursement data (January 3, 2017, to February 8, 2018) and extracted (by payor) the number of encounters and claim adjustment codes, and defined reimbursed as a payment greater than 0. For statistical computing and graphics, we used Prism 5 (GraphPad software, La Jolla, CA) and/or R (version 3.3.3; <https://www.r-project.org/>).

RESULTS {#s12}
=======

Patient Characteristics {#s13}
-----------------------

Between January 2015 and May 2017, we performed rapid *EGFR* testing on 243 consecutive newly diagnosed patients with metastatic NSCLC (approximately two patients/week; [Table 1](#T1){ref-type="table"}). The median age at diagnosis was 69.1 years (range, 34 to 92 years). Most cancers were adenocarcinomas (n = 205; 84%). Never- or light-smokers comprised 54% (n = 132 of 243) of the rapid cohort. Forty-three (18%) of 243 tumors harbored *EGFR* mutations. One patient had an uncommon *EGFR* exon 19 deletion that did not involve the ELREA sequence (p.E746-A750).^[@B16]^ [Figure 2A](#f2){ref-type="fig"} shows representative images of positive rapid test results. Although it was our intention that all specimens would also be submitted for NGS, specimens from nine patients were not referred for NGS. Among the remaining 234 patients, 23 (10%) did not have NGS results because of insufficient tissue or technical failure of NGS (Data Supplement).

###### 

Clinicopathological Characteristics of Rapid Cohort

![](PO.17.00299t1)

![Rapid EGFR assay and turnaround times compared with next-generation sequencing (NGS)--based genotyping. (A) The rapid *EGFR* assay consists of three separate reactions: a sizing assay to identify exon 19 (ELREA sequence) deletions and two single-nucleotide extension reactions to identify p.T790M and p.L858R missense mutations. (B) After validation (last quarter of 2014), we implemented rapid *EGFR* genotyping in January 2015. Scatter plots portray turnaround times of all 243 rapid EGFR samples (Jan 2015 to May 2017; black, *EGFR* wild type \[WT\]; red, *EGFR* mutation \[mut\] detected) and all specimens that underwent NGS (gray dots) during this period. Note that process improvements have led to a reduction in average turnaround times for both assays (lines).](PO.17.00299f2){#f2}

Diagnostic Utility of the Rapid *EGFR* Assay {#s14}
--------------------------------------------

**Improvement in turnaround time.** First, we compared the turnaround times of the rapid and NGS assays by reviewing all specimens submitted for genotyping between July 2014 and January 2017 ([Fig 2B](#f2){ref-type="fig"}). The median turnaround time in workdays for NGS genotyping was 14 days compared with 7 days for rapid testing (*P* \< .001, *t* test). Forty-one of the 43 patients (95%) who tested positive for *EGFR* mutations with the rapid assay were also tested for mutations using NGS. In this group of patients, the median turnaround time for rapid EGFR and NGS was also 7 days and 14 days, respectively. Overall, rapid EGFR testing significantly reduced the time from biopsy to availability of *EGFR* results.

**Concordance between rapid assay and NGS genotyping.** Next, we assessed the technical performance of the rapid EGFR test by comparing rapid with NGS results. Through NGS, we identified one additional low-level (allelic fraction, approximately 4%) p.L858R case, which was missed by rapid EGFR testing ([Fig 3](#f3){ref-type="fig"}). Compared with NGS, we did not detect any false-positive results with the rapid EGFR test. Overall, the sensitivity and specificity of the rapid EGFR test to detect the *EGFR* mutations of interest were 98% and 100%, respectively. The mutation-spectrum of the tumors that underwent rapid testing is depicted in [Figure 3](#f3){ref-type="fig"}, and the Data Supplement shows probabilities of therapeutically actionable variants.

![Integration of molecular-genetic testing in 243 patients with non--small-cell lung cancer who underwent rapid *EGFR* genotyping. The heatmap portrays clinicopathologic features (top three rows), rapid EGFR results, and key molecular drivers along with the results of next-generation sequencing (NGS)--based fusion detection, fluorescence in-situ hybridization (FISH), and NGS panel results. Key findings include (1) an isolated false-negative rapid EGFR result (arrow), (2) the inability of the rapid *EGFR* test to detect *EGFR* mutations at other residues, (3) identification of at least one underlying driver mutation in more than 50% of all tested cases by using the integrated molecular diagnostic approach, and (4) the association between clinicopathologic features and certain key drivers (eg, never-smoking women with adenocarcinoma and *EGFR v* \> 10 pack-year smoking history and *KRAS*). Adeno, adenocarcinoma; AdSQ, adenosquamous; Delins, insertion/deletion; Ex19del, exon 19 deletion; Ex20ins, exon 20 insertion; GCCa, giant cell carcinoma; LCNEC, large-cell neuroendocrine carcinoma; N/A, not applicable; Non-syn, nonsynonymous; PM, point mutation; py, pack year; SarcCa, sarcomatoid carcinoma; SQ, squamous.](PO.17.00299f3){#f3}

Clinical Utility of Rapid EGFR Testing {#s17}
--------------------------------------

**TTI of TKI therapy.** In 2009, a pivotal study demonstrated that empiric initiation of an EGFR TKI on the basis of clinical characteristics alone could be detrimental.^[@B17]^ As a result, demonstration of an *EGFR* mutation is a prerequisite for TKI initiation. Therefore, we selected time to EGFR TKI as the primary measure of clinical utility of the rapid EGFR test. To determine whether expedited reporting of *EGFR* results decreased the TTI of TKI therapy, we compared the median time to initiation of TKI therapy in our rapid cohort to that of a historical cohort of 121 patients diagnosed with *EGFR*-mutant NSCLC between 2011 and 2014 (before our rapid testing initiative); during this time, first-line treatment of *EGFR*-mutant NSCLC with an EGFR TKI was the standard of care at our institution.

Forty-one (95%) of 43 patients in the rapid cohort had sufficient follow-up after diagnosis to confirm the date of initiation of therapy. Of these patients, 39 (95%) received an EGFR TKI as first-line therapy, compared with 98 patients (81%) in the historical cohort (*P* = .04, Fisher's exact). The median TTI of EGFR TKI therapy was 3.1 weeks for the rapid cohort compared with 5.3 weeks for the historical group (*P* \< .001, log-rank; hazard ratio, 3.4; 95% CI, 2.1 to 5.6; [Fig 4A](#f4){ref-type="fig"}). We reviewed the medical records of the 39 patients with *EGFR*-mutant disease who underwent both rapid testing and NGS to determine whether TKI therapy was initiated before NGS results. We were not able to assess this end point for four patients because of the following: (1) timing of TKI initiation could not be confirmed (n = 1); (2) an EGFR TKI was not initiated during the follow-up period (n = 1), or (3) initiation of TKI therapy was prompted by prior outside testing that predated results at our institution (n = 2). Among the remaining 35 patients, 17 (49%) started TKI therapy before NGS results ([Fig 4B](#f4){ref-type="fig"}). Of note, apart from one patient who had de novo high-level *MET* amplification and a single case in which an *EGFR* T790M mutation was present at diagnosis,^[@B18]^ none of the other tumors harbored baseline co-alterations that would be expected to compromise the efficacy of EGFR TKI monotherapy ([Fig 3](#f3){ref-type="fig"}).

![Therapeutic and clinical utility of rapid *EGFR* genotyping. (A) Event curve that shows rapid EGFR test reporting times and a comparison of the tyrosine kinase inhibitor (TKI) initiation times (relative to date of diagnosis) for patients in the rapid and historical cohorts. (B) Timeline of 43 patients with *EGFR*-mutant lung cancer. The top three patients did not receive epidermal growth factor receptor (EGFR)--directed therapy during the follow-up period. The second block shows the 49% of patients (n = 17 of 35 patients) with *EGFR*-mutant disease who started a TKI before next-generation sequencing (NGS) results were available. The third block shows patients who initiated EGFR-directed therapy after NGS results were available. (C) Response to the EGFR inhibitor osimertinib in a patient with non--small-cell lung cancer who underwent ultra-rapid EGFR testing: (left) pretreatment image and (right) response after 3 weeks; arrow indicates primary tumor. (D) Comparison of rapid test times (average) and the eight patients tested with the ultra-rapid protocol ([Fig 1C](#f1){ref-type="fig"}); inset shows event curve comparison of time to initiation of TKI between the rapid and ultra-rapid subsets. (E) Turnaround times for rapid (gray) and ultra-rapid (blue) workflows in a 9-month extended standard-of-care evaluation phase; red, cases with an *EGFR* mutation. Outliers in reporting times are due to delays in block retrieval or repeated testing. (F) Reimbursement analysis: pie chart depicts the overall frequency of reimbursement; columns illustrate the payor-based number of reimbursed encounters. mut, mutated; WT, wild type.](PO.17.00299f4){#f4}

Implementation of an Ultra-Rapid EGFR Testing Workflow {#s19}
------------------------------------------------------

Certain patients with aggressive disease may benefit the most from rapid initiation of effective therapies with fast onset. For example, several of our patients presented with compromised neurologic function (eg, vision loss or ataxia) or severe symptoms that required hospitalization. Rapid EGFR testing can be rushed for these patients; however, our protocols have already been optimized and are not readily amenable for a reduction in turnaround time. To address this need, we launched a multidisciplinary ultra-rapid workflow to improve preanalytical processes ([Fig 1C](#f1){ref-type="fig"}). The ultra-rapid *EGFR* testing pathway uses fresh tissue for confirmation of cancer diagnosis and same-day nucleic acid extraction. In cases where ultra-rapid testing fails, the formalin-fixed tumor sample serves as a safeguard and allows for traditional molecular testing. A case report of a patient who benefitted from this effort and a summary of the experience to date are described in the next section.

Case report. {#s20}
============

Therapeutic utility of ultra-rapid testing. {#s21}
-------------------------------------------

A 79-year-old male never-smoker presented with 1 month of persistent cough and 1 day of inability to walk or swallow. Imaging studies revealed a 4-cm left lung mass ([Fig 4C](#f4){ref-type="fig"}), lung nodules, and lesions throughout the brain and leptomeninges. The lung mass was sampled via percutaneous needle biopsy 4 days into admission, and cytopathology and frozen sections confirmed adenocarcinoma. Same-day extraction and next-day testing revealed an *EGFR* exon 19 deletion. He initiated treatment with osimertinib on day 7 of hospitalization. Osimertinib was selected on the basis of its activity against leptomeningeal disease.^[@B19]^ Within days, the cough resolved, and the patient experienced marked improvement in his swallowing and regained the ability to walk. Scans obtained 3 weeks into therapy demonstrated response in the chest ([Fig 4C](#f4){ref-type="fig"}) and CNS, including leptomeningeal sites.

Ultra-rapid testing turnaround time and results. {#s22}
------------------------------------------------

Between May 2017 and September 2017, a total of eight patients participated in the ultra-rapid testing program ([Fig 4D](#f4){ref-type="fig"}). Seven tumors harbored *EGFR* mutations, whereas one tumor contained a *ROS1* rearrangement. [Figure 4D](#f4){ref-type="fig"} illustrates the difference in turnaround time for the rapid and ultra-rapid tests and the time to initiation of TKI therapy for patients tested through each workflow ([Fig 4D](#f4){ref-type="fig"} inset). The median turnaround time for *EGFR* results and the median TTI of an EGFR TKI were 1.5 days and 9 days, respectively. The sites of disease and presenting symptoms of these patients are detailed in the Data Supplement, which also summarizes our ultra-rapid workflow.

Rapid *EGFR* testing is operationally and financially sustainable. {#s23}
------------------------------------------------------------------

After review of the data presented here, we offered the rapid (and ultra-rapid) workflows as standard of care tests beginning in July 2017. Between July 2017 and March 2018 ([Fig 4E](#f4){ref-type="fig"}), the average (mean ± standard deviation) turnaround time was 3 ± 1.5 days for rapid (ie, formalin-fixed paraffin-embedded--based) testing and was 0.81 ± 0.4 days for the ultra-rapid (ie, frozen) workflow, respectively. Review of 214 clinical encounters with 1,475 line items of reimbursement data showed large variability between payors (range, 0% to 100%) and that, overall, 63% of encounters received reimbursement ([Fig 4F](#f4){ref-type="fig"}). These data indicate that rapid EGFR testing in our practice is operationally and financially sustainable.

DISCUSSION {#s24}
==========

Here, we report the results of a quality improvement initiative to explore parallel testing with a rapid EGFR assay and NGS in newly diagnosed NSCLC. To our knowledge, this is the first report of systematic prospective implementation of co-testing. Our findings emphasize the diagnostic, clinical, and therapeutic utility of rapid EGFR testing.

Metastatic NSCLC is a devastating and incurable disease for which the prognosis is highly dependent on identification of actionable molecular drivers.^[@B2]^ The established efficacy of US Food and Drug Administration--approved targeted therapies in specific NSCLC subsets and the increasing number of investigational compounds underscore the necessity of identification of molecular alterations in a timely fashion. NGS panels deliver comprehensive genotypes, but reporting delays can be substantial. Several studies suggest that genotyping with multiple single-gene assays may reduce reporting time^[@B20],[@B21]^; however,selective interrogation of the ever-expanding set of targets is impractical and may be limited by tissue availability.^[@B22]^

At the time our initiative began, consensus guidelines supported testing newly diagnosed patients with NSCLC for *EGFR* mutations and rearrangements in *ALK* and *ROS1*.^[@B9]^ These mutually exclusive genetic alterations are predominantly found in never- or light-smokers.^[@B13],[@B23]^ Testing these alterations in two stages (ie, restriction of testing for rearrangements to patients whose disease is wild type for *EGFR* mutations) may lead to unnecessary delays between diagnosis and initiation of treatment for a significant proportion of patients and potentially steer symptomatic patients away from molecularly targeted treatments. Through co-testing, we detected *ALK* and *ROS1* rearrangements in 11 and six patients, respectively, and identified molecular alterations with promising investigational therapies in more than 40 additional patients ([Fig 3](#f3){ref-type="fig"}). The comprehensiveness of NGS results comes at a price of longer turnaround time. For example, in a recent retrospective analysis that involved 15 community oncology centers, the median turnaround time for *EGFR* testing and NGS was 23 days and 30 days, respectively.^[@B24]^ Although this practice is likely more common in the community setting, where in-house testing is infrequent, one study demonstrated that 19% of patients with *EGFR* mutations or *ALK* rearrangements at an academic medical center in Canada initiated first-line chemotherapy before testing results became available.^[@B11]^ The sequence of therapies may be particularly important for those patients initially treated with immunotherapy, because recent studies demonstrate that immunotherapy is seldom effective for *EGFR*-mutant NSCLC and that treatment with immunotherapy before targeted therapy increases the likelihood of the development of significant toxicities.^[@B25]-[@B27]^ Given these data, we believe that rapid testing should be performed in parallel with full NGS genotyping.

With a parallel-testing approach, we successfully performed rapid testing and NGS in 90% of patients in our initiative with material from a single biopsy. Because half of the patients with tissue/DNA that was insufficient for the full NGS were effectively tested for both *ALK* and *ROS1* rearrangements using either fluorescence in-situ hybridization or the fusion assay, 95% of the patients in the rapid cohort met the minimum molecular testing requirement proposed by current ASCO guidelines. Because our success rate compares favorably with other studies that evaluated biopsy specimen adequacy,^[@B28]^ concerns about tissue availability should not deter implementation of similar testing strategies. However, we acknowledge that the tissue failure rate may be higher if express testing for other alterations is performed in conjunction with rapid EGFR testing and NGS. To offset this risk, the ultra-rapid testing protocol specifies that additional cores should be obtained if safe and feasible (Data Supplement). Nonetheless, limitations of tissue-based genotyping have kindled interest in plasma genotyping. Although PCR-based plasma genotyping is an expedient alternative to NGS-based tissue genotyping, the sensitivity of liquid biopsy for detection of *EGFR* mutations is lower than what we report here with the rapid assay.^[@B29],[@B30]^

Despite the high sensitivity and specificity of the rapid assay, half of the patients in our study did not start TKI therapy before NGS results were available ([Fig 4B](#f4){ref-type="fig"}). The inability to translate faster turnaround times into intervention could be the result of timing of drug shipment or socioeconomic factors. Participants in the rapid genotyping group started TKI therapy approximately 2 weeks before patients in the historical cohort. Because TTI was assessed retrospectively for the historical cohort, the median of 37 days between diagnosis and TKI therapy might be an overestimate; however, a similar delay was observed in another study.^[@B31]^ It also is conceivable that the difference in TTI might be explained by process improvements over time that have shortened the interval between requests for and receipt of a drug from specialty pharmacies. Because TKI use predated NGS results in approximately 50% of patients, the reduction in time to TKI initiation in the rapid group relative to the historical cohort might also reflect faster NGS reporting times. Indeed, our average turnaround time for NGS is approximately 10 days currently versus approximately 2 weeks in the past ([Fig 2B](#f2){ref-type="fig"}). The scale of NGS panels currently precludes significant reduction, and the median and mean turnaround times for NGS results in the ultra-rapid cohort were 9 and 10 days, respectively. In contrast, we showed that PCR-based approaches can consistently produce rapid results within 24 hours of biopsy ([Fig 4E](#f4){ref-type="fig"})---a benchmark that is currently impossible to achieve with NGS.

It remains to be established whether initiation of an EGFR TKI earlier improves overall survival.^[@B32],[@B33]^ The impact of the timing of EGFR therapy on overall survival has become even more difficult to assess because of widespread use of next-generation EGFR TKIs capable of overcoming TKI resistance in a subset of cases. As a result of the short duration of follow-up of our rapid cohort and imbalances between the rapid and historical groups (including enrollment of patients in the rapid cohort into a consolidation radiation protocol), we were unable to evaluate differences in progression-free survival on EGFR-directed therapy. Despite these limitations, there are notable advantages to implementation of an assay that increases first-line use of EGFR TKIs, including cost savings relative to up-front treatment with chemotherapy and the potential to induce faster and more robust responses in symptomatic patients.^[@B4],[@B34]-[@B38]^ Although *EGFR*-mutant NSCLC is classically regarded as an indolent disease, many patients present with widely metastatic disease (Data Supplement).^[@B39],[@B40]^ The superior efficacy of EGFR TKIs relative to chemotherapy against brain metastases and the potential to defer brain radiation for these patients underscore the importance of rapid identification of *EGFR* mutations.^[@B41],[@B42]^ The small number of patients with *EGFR*-mutant disease in our study also limits the potential impact of our findings. Finally, we recognize that successful execution of this initiative was dependent on establishment of the infrastructure to support rapid testing (Data Supplement). Thus, our findings may not be generalizable to all practice settings. However, many laboratories are proficient in performing targeted *EGFR* genotyping,^[@B43]^ and our extended standard of care evaluation ([Fig 4E](#f4){ref-type="fig"}) and reimbursement analysis ([Fig 4F](#f4){ref-type="fig"}) indicate operational and financial sustainability.

In summary, we demonstrate that expedited *EGFR* genotyping enables early intervention with targeted therapies and allows symptomatic patients to access effective treatments. The growing number of actionable targets substantiates the need for diagnostic strategies that expedite molecular analysis.
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